- Poster presentation
- Open Access
Antibody disulfide bond reduction during process development: Insights using a scale-down model process
© Ruaudel et al. 2015
- Published: 14 December 2015
- Copper Sulfate
- Free Thiol
- Decline Phase
- Free Thiol Group
- Upstream Process
Keywords:mAb reduction / disulfide bond scrambling / free thiols
During the development of the production process for a monoclonal antibody (mAb), we observed a significant increase in the reduction of interchain disulfide bonds following pilot scale protein A purification of the produced antibody (IgG1κ).Different companies have reported the presence of fragmented IgG1 antibodies in the clarified cell culture fluid (CCCF) at manufacturing scale. It has been demonstrated  that enzymes of the thioredoxin system, released during the decline phase of the culture, were responsible for the interchain disulfide bond reduction. However, our observations were different as the majority of the interchain disulfide bonds were still oxidized in the CCCF. The massive fragmentation of interchain disulfide bonds occurred only after pilot scale protein A purification step. This study presents our insights in antibody reduction using scale-down models.
First, the mAb fragmentation phenomenon was reproduced at small scale by incubation of mAb containing CCCF with cell lysate followed by SDS-PAGE with and without NEM (N-ethylmaleimide). NEM is known to protect free thiol groups during sample preparation for SDS-PAGE .
Second, a scale down model of the bioreactor process was established in order to understand which process parameters led to the massive reduction and hence fragmentation of the mAb during the pilot scale protein A purification process.
MAb reduction is a complex mechanism, which was found in our case to be related to the upstream process rather than a specific cell line. We observed this phenomenon with two different IgG1κ expressing CHO cell lines in two different non-optimized processes, in which the cell viability decreased quickly and sharply. As this viability decline was identified to be the root cause for the release of thiols in the supernatant, the most evident way to prevent the reduction phenomenon might be the modification of the process conditions in order to maintain a good viability throughout the entire upstream process until the clarification step. Further, different IgG formats have been shown to have different sensitivities to reduction , thus choosing the right IgG format might be helpful to avoid reduction. The addition of copper sulfate has been also identified as a treatment in the literature . Added at the beginning of the culture, copper sulfate maintains the supernatant in an oxidative state until the end of the culture and thus prevents an increase of free thiols in the supernatant.
All Glenmark teams involved in this project (CLD, USP, DSP, QC, Immunology and AE)
- Melody Trexler-Schmidt, Sandy Sargis, Jason Chiu, Stefanie Sze-Khoo, Melissa Mun, Yung-Hsiang Kao, Michael Laird: Identification and Prevention of Antibody Disulfide Bond Reduction During Cell Culture Manufacturing. Biotechnology and Bioengineering. 2010, 106 (3):Google Scholar
- Hongcheng Liu, Georgeen Gaza-Bulseco, Chris Chumsae, Abigail Newby-Kew: Characterization of lower molecular weight artefact bands of recombinant monoclonal IgG1 antibodies on non-reducing SDS-PAGE. Biotechnol Lett. 2007, 29: 1611-1622.View ArticleGoogle Scholar
- Hutterer KM, Hong RW, Lull J, Zhao X, Wang T, Pei R, Le ME, Borisov O, Piper R, Liu YD, Petty K, Apostol I, Flynn GC: Monoclonal antibody disulfide reduction during manufacturing: Untangling process effects from product effects. MAbs. 2013, 5 (4): 608-13. Jul-Aug;. doi: 10.4161/mabs.24725. Epub 2013 Apr 18PubMedPubMed CentralView ArticleGoogle Scholar
- Wendy Chaderjian, Edward Chin, Reed Harris, Tina Etcheverry: Effect of copper sulfate on performance of a serum-free CHO cell culture process and the level of free thiol in the recombinant antibody expressed. Biotechnol Prog. 2005, 21: 550-553.Google Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.